19q13.11 microdeletion concomitant with ins(2;19)(p25.3;q13.1q13.4)dn in a boy: potential role of  in the associated phenotype by unknown
Venegas-Vega et al. Molecular Cytogenetics 2014, 7:61
http://www.molecularcytogenetics.org/content/7/1/61CASE REPORT Open Access19q13.11 microdeletion concomitant with ins
(2;19)(p25.3;q13.1q13.4)dn in a boy: potential role
of UBA2 in the associated phenotype
Carlos Venegas-Vega1,2, Karem Nieto-Martínez2, Alejandro Martínez-Herrera2, Laura Gómez-Laguna1,
Jaime Berumen2,3, Alicia Cervantes1,2, Susana Kofman1,2 and Fernando Fernández-Ramírez1*Abstract
The 19q13.11 microdeletion syndrome (MIM613026) is a clinically recognisable condition in which a 324-kb minimal
overlapping critical region has been recently described. However, genes not included within this region, such as WTIP
and UBA2, have been proposed to contribute to the clinical characteristics observed in patients. Using cytogenetic
techniques, single nucleotide polymorphism arrays, and the quantitative polymerase chain reaction, we identified a
novel case with a 2.49-Mb deletion derived from a de novo chromosomal rearrangement. Based on a review of the
literature, we support the notion that UBA2 haploinsufficiency could contribute to the phenotype of this rare genomic
disorder. UBA2 belongs to a protein complex with sumoylation activity, and several transcription factors, hormone
receptors, and signalling proteins related to brain and sexual development are regulated by this post-translational
modification. Additional clinical reports and further research on UBA2 molecular function are warranted.
Keywords: 19q13.11 microdeletion syndrome, Chromosomal rearrangement, UBA2Background
The 19q13.11 microdeletion syndrome (MIM613026) is a
clinically recognisable condition that has been recently
identified by molecular karyotyping techniques. Only 11
cases have been reported, and the common clinical
characteristics include intellectual disability, growth re-
tardation, microcephaly, variable signs of ectodermal
dysplasia, slender habitus, and genital malformations
in males [1-7]. A minimal overlapping critical region
(MOCR) of 324 kb has recently been identified ([hg18]
chr19: 39,803,651-40,127,916) [4]; this MOCR includes
four genes of the zinc finger family containing the
Krüppel-associated box (KRAB domain) and two non-
coding RNA (ncRNA) genes. Here, we report the first
case of 19q13.11 microdeletion syndrome caused by a
chromosomal rearrangement and discuss the potential
role of UBA2 in the phenotype of affected individuals.* Correspondence: ffernandez@ciencias.unam.mx
1Unidad de Genética, Hospital General de México, Dr. Balmis 148, México, D.F
06726, México
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Clinical description
The proband is the third child of non-consanguineous
parents. Prior to his birth, the mother had one spontan-
eous abortion. Caesarean section was performed at
36.5 weeks of gestation because of preeclampsia. At
birth, the patient showed low weight (<3rd centile) and
length in the 10th–25th centile. The Apgar score was
7/10. Developmental delay, feeding difficulties, and re-
current upper airways infections compromised his early
infancy. He underwent several surgical procedures be-
cause of bilateral hip dislocation, clubfeet varus, and
hypospadias. At 5 years and 3 months of age, he had
one febrile seizure, and 2 months later, he underwent
surgery for bilateral inguinal hernia and left orchidopexy.
Clinical evaluation was performed at 6 years and 7 months,
and the weight was 16.1 kg (<3rd centile), the height was
112 cm (10–25 centile), and the occipital-frontal circum-
ference was 46.5 cm (<3rd centile). The clinical findings
are described in Figure 1a–d and Table 1. Hormonal
studies, including analyses of FSH, LH, testosterone,
oestradiol, progesterone, TSH, T3, T4, ACTH, cortisol,
and growth hormone (basal and post-stimulation withCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Figure 1 Proband phenotype and cytogenetic analysis. Proband at the age of 6 years and 7 months, showing (a) slender habitus with little
subcutaneous fat and scars from the surgery for inguinal hernias; (b) cutis aplasia in midline scalp; (c) sparse hair, long face, high frontal hair line,
sparse eyebrows and eyelashes, hypoplastic alae nasi, and low-set ears; and (d) shawl scrotum. (e) Partial GTG-banding karyotype of the patient
showing normal and derivative chromosomes 2 and 19. (f) Normal and derivative chromosomes 2 and 19 showing FISH signals. Note the signal
of 19q (orange) at the top of der(2), followed by the 2p (green) signal and the 2q (orange) signal at the end of the chromosome. der(19) shows
only the 19p (green) signal. (g) Diagram illustrating the insertion of the segment from 19q13.12 to 19q13.43 in 2p25.3, with concomitant deletion
of 19q13.11-q13.12.
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audiometry and ECG yielded normal results.
Results
Karyotyping revealed a de novo rearrangement between
chromosomes 2p25.3 and 19q13.1 (Figure 1e). FISH
analysis with subtelomeric probes showed a signal of 19q
on der(2), which retained the signal of 2p and 2q, whereas
der(19) presented only the 19p signal (Figure 1f ). The
patient’s chromosomal complement was 46,XY,ins(2;19)
(p25.3;q13.1q13.4)dn.ish ins(2;19)(p25.3;q13.1q13.4)(D1
9S238E+,U32389+,D2S447+;129F16/SP6+,D19S238E-).
Microarray analysis indicated a 2.49-Mb de novo deletion
(arr[hg19] 19q13.11-q13.12 (33,565,628–36,055,467) ×
1 dn), which was confirmed by quantitative PCR (seeAdditional file 1: Figure S1). Trio SNP analysis of
chromosome 19q revealed that the deleted allele was pa-
ternal, as indicated by 13 informative markers within the
deletion (p < 1 × 10-30) (Additional file 2: Table S1). Taken
together, these data indicate that the patient’s rearrange-
ment corresponds to an insertion coupled with an intersti-
tial deletion. His final chromosomal complement was 46,
XY,ins(2;19)(p25.3;q13.12q13.43),del(19)(q13.11q13.12)dn.
Discussion and conclusions
Eleven cases of 19q13.11 microdeletion syndrome have
been reported [1-7], and two additional cases are anno-
tated in the DECIPHER database (patients 127 and 3776)
[8]. The parental origin of the reported 19q13.11 deletions
suggests that an imprinting effect associated with this
Table 1 Clinical features of patients with 19q13.11 deletion syndrome (MIM613026)
Patient 1 2 3 4 5 6 7 8 9 10 11 Proband Total
Size of the deletion (Mb) 11 6.16 4.27 3.19 2.4 1.74 2.63 7.87 1.37 8.16 2.30 2.49
Gender F M M M M M F M F F M M 4 F/8 M
Age [years. months] 3.0 6.0 9.2 5.0 4.10 14 8.0 ϕ 6.5 5.6 1.6 6.7
Preterm delivery [≤38 weeks] + + + + + + + + + + 10/10
Development characteristics
Prenatal growth retardation + + + + + + + + + - + + 11/12
Feeding problems + + + + + + - + + + + 10/11
Postnatal growth retardation + + + + + + + + + + + 11/11
Slender habitus + + + + - + - + + 7/9
Little subcutaneous fat + + + + - + + 6/7
DD/ID + + + + + + + + + + + 11/11
Speech disturbance + + + + + + + + + + + 11/11
Microcephaly + + + + + + + + + + + 11/11
Minor Facial dysmorphic features* + + + + + + + + + + + + 12/12
Long face + + + + + + -a + + + + 10/11
High frontal hairline + + + +b + + + + + + 10/10
High forehead + + + + + + + + + 9/9
Eye abnormalities +c - +d +e - +f +c 5/7
V-shaped nasal tip + + + + + + + + 8/8
Hypoplastic nasal alae + + + + + + + + 8/8
Low-set columella + + + + + 5/5
Thin lips + + + + + + + + + + 10/10
Retro-micrognathia + + + + + + + + + - + + 11/12
Large ears or low-set ears + + + + + + + + + + + 11/11
Signs of ectodermal dysplasia
Aplasia cutis in midline of scalp + + + + + + - + - + + 9/11
Thin/dry skin + + + + + - - + 6/8
Thin-sparse hair + + + + + - + - - + 7/10
Thin-sparse eyebrows/eyelashes + + + + + + + + - - + 9/11
Teeth abnormalities +g +h - +i +j - +j 5/7
Dysplasic nails + + - + - - + - - + 5/10
Genital abnormalities
Hypospadias NA + + + + + NA + NA NA + + 8/8
Testicular ectopia NA - + + + - NA NA NA + + 5/7
Bifid scrotum NA + - - + - NA NA NA - + 3/7
Extremity abnormalities
Long/tapering fingers + + + + + + + + 8/8
Clinodactyly of the 5th finger + + + + + + - + 7/9
Abnormal positioning of the feet + + + - + 4/5
Overlapping of the toes + + - - - - - + + 4/9
Cutaneous syndactyly F/T - + + + + - - + + + 7/10
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Table 1 Clinical features of patients with 19q13.11 deletion syndrome (MIM613026) (Continued)
Others
Recurrent airways infections + + + + - + + 6/7
Heart disease + + - + - + - + - 5/9
Inguinal hernia + + + 3/3
Febrile seizure + + + 3/3
Endocrine abnormalities + + + - 3/4
Patients: (1) Kulhayra et al, [1] (2–4) Malan et al, [2] (5) Schuurs-Hoeijmakers et al, [3] (6–7) Gana et al, [4] (8) Lin et al, [5] (9) Forzano et al, [6] and (10–11)
Chowdhury et al. [7] The total number of patients with a specific phenotype differs depending on whether the phenotype was specifically mentioned in the reports; only
those reported are counted, and blank spaces correspond to data not documented. *We included the reported facial features and also features that were not reported
in cases where evaluation of the published photographs was possible. Abbreviations: F, female; M, male; ϕ, foetus aborted at the 28th week of gestation;
DD/ID, developmental delay/intellectual disability; F/T, fingers or toes; +, present; -, absent; NA, not applicable. Clinical findings: (a)round face, (b)frontal upsweep of hair,
(c)strabismus, (d)microcornea-cataract, (e)epiblepharon, (f)astigmatism, (g)single median incisor, (h)teeth irregularly placed, (i)hypodontia and (j)multiple caries.
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ternal cases have been documented [1], including the one
reported here. To our knowledge, this is the first case of a
19q13 deletion derived from a chromosomal rearrange-
ment, which probably involved three breakpoints in
chromosome 19 (at q13.11, q13.12, and q13.4) and one
breakpoint in 2p25.3 (Figure 1g).
This patient displayed the main clinical features of
19q13.11 microdeletion syndrome (Table 1), and his de-
letion affected 49 genes, including those at the MOCR
(Figure 2). Among these genes, ZNF302, ZNF181, ZNF599,
and ZNF30 belong to the KRAB-containing zinc finger
subfamily and have been described as ubiquitous tran-
scription repressors [9], whereas the ncRNA genes
LOC400685 and LINC00904 are still uncharacterised.
Excluding one case involving a female individual
(Patient 7, Table 1) [4], all of the reported deletions af-
fected three genes in addition to those at the 324 kb
MOCR: UBA2, WTIP, and SCGB2B2 (Figure 2). SCGB2B2
is a member of the secretoglobin protein family whose
function is unknown to date. These proteins are found at
high concentrations in various human fluids and have
been recently found to play immunomodulatory roles
[10]. The other genes, UBA2 and WTIP, could contribute
to several clinical characteristics. Analysis of their genomic
and functional properties, such as overlapping with copy
number variant (CNV) regions and haploinsufficiency
(HI), may help to clarify their potential role in this syn-
drome. A prediction score for HI has been generated from
highly significant differences in genomic, evolutionary,
functional and network properties between 1,079 haplo-
sufficient genes and 301 genes known to display HI [11].
In this model, ranks between 0% and 10% indicate that a
gene is more likely to exhibit HI. For instance, WTIP has
been proposed as a candidate gene associated with hypo-
spadias [4,7]. This gene is located in a copy number vari-
ant (CNV) region (i.e. the deletion has been observed
in >1% of healthy control samples) [12,13] and it is not
likely to exhibit HI (57.1%). However, this gene should not
be excluded as a candidate because of its functionalcharacteristics [4]. The upstream gene UBA2 has also
been proposed as a candidate for this syndrome [3],
and it was also deleted in all of the reported male pa-
tients (Figure 2). Interestingly, this gene is strongly pre-
dicted to display HI (2.5%) [11] and no deletion variant
has been observed in its locus [13]. Moreover, functional
interactions between WTIP and UBA2 are possible, as
these proteins share common physical interactors (http://
string-db.org) [14].
UBA2 participates in the sumoylation process as a sub-
unit of the dimeric E1-activating enzyme. Sumoylation is a
post-translational modification in which a small ubiquitin-
like modifier (SUMO) protein is ligated to a target protein,
affecting its structure, intracellular localisation, or activity.
Several transcriptional regulators, hormone receptors, and
cell signalling proteins are regulated in this manner [15].
For instance, the androgen receptor (AR) is negatively reg-
ulated by sumoylation at its synergy control (SC) motifs.
This mechanism could be important for normal AR func-
tion, as suggested by the finding of a P390S mutation in
the first SC motif of the AR in a paediatric patient with
hypospadias (reviewed by Mukherjee et al. [16]). There-
fore, we hypothesize that HI of UBA2 could contribute to
the genital abnormalities observed in male patients, either
by an autonomous mechanism or by molecular interac-
tions among the deleted genes. A female individual with a
congenital hydroureter presented a 19q13.1 deletion not
overlapping with the MOCR but still affecting UBA2 [7].
This finding indicates that careful urogenital evaluation of
female patients is also important. Other transcription fac-
tors relevant to sexual determination and differentiation,
such as SOX9 and SF1, are regulated by sumoylation [17].
Therefore, it is possible that this post-translational
modification could be particularly important in sexual
development. Sumoylation is clearly emerging as a key
determinant in the regulation of neuronal maturation and
synapse formation and activity at different stages of brain
development [18]. Hence, it is possible that HI of UBA2
could also contribute to the intellectual disability pheno-
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Patient 1 (11 Mb) 1
Patient 2  (6.16 Mb) 2
Patient 3   (4.27 Mb) 2
Patient 4 (3.15 Mb) 2
Patient 5 (2.4 Mb) 3
DECIPHER 37768 (5.69Mb)
DECIPHER 1278 (MXX, 2.03Mb)
Patient 6 (1.74Mb) 4
Patient 7 (2.63Mb) 4
Patient 8 ( 7.87Mb) 5
Patient 9 (1.37Mb) 6
Patient 10 (8.16 Mb) 7
Patient 11 (2.30Mb) 7
Proband   (2.49Mb)
φ,
Figure 2 Schematic summary of the reported 19q13.11 microdeletions, according to the human genome assembly hg19 (GRCh37).
An ideogram of Chr. 19q12-q13.12 is displayed at the top. The shaded region between the solid black lines represents the MOCR of approximately
324 kb ([hg19] chr19:35,111,811-35,436,076). The solid red line at the left indicates the deletion breakpoint of the patient reported by Forzano et al.
([hg19] chr19:34,957,764-34,983,674) [6], which affects the last two exons of UBA2. The proximal breakpoint of the male patient reported by Gana et al.
[4] ([hg18]chr19:39,608,712-39,626,575) is indicated by a short dotted line; this deletion affects the last 11 exons of UBA2. The gene map is displayed at
the bottom, and qPCR validation targets are circled. Patients are numbered according to Table 1, and deletions are indicated with grey (female) and
black (male) bars; the size is indicated in parentheses. MXX is a 46,XX male; ϕ, male foetus aborted at the 28th week of gestation.
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In conclusion, we report a novel case of 19q13.11 micro-
deletion syndrome caused by a chromosomal rearrange-
ment and suggest that UBA2 haploinsufficiency could
contribute to the phenotypic outcome of the male pa-
tients. Additional clinical reports and future research on
its molecular function will clarify its role in this
syndrome.
Methods
G-band karyotyping was performed according to standard
protocols. The subtelomeric regions of chromosomes 2
and 19 were analysed by FISH using mixtures #2 and #14
from ToTelVysion multicolour DNA probes (Vysis
Abbott Laboratories, Abbott Park, Illinois, USA) ac-
cording to the procedure described by the supplier.
Mix #2 contains probes for 2p (U32389, green), 2q(D2S447, orange), chromosome X centromeric region
(aqua) and Xq/Yq subtelomeric region (green/orange).
Mix #14 has only 19p (129F16/SP6, green) and 19q
(D19S238E, orange) probes.
Initial copy number and genotyping analyses were per-
formed on the trio using GeneChip Human Mapping
Sty 250 K arrays (Affymetrix Inc., Santa Clara, CA,
USA), and an additional set consisting of 30 Mexican
mestizo controls was used as reference. This microarray
contains probes corresponding to ~238,000 single nu-
cleotide polymorphism (SNP) positions, which are dis-
tributed across the genome with a median inter-marker
distance of approximately 5 kb. To refine the deletion
breakpoints, the high-density Genome-Wide Human SNP
6.0 array was used for copy number analysis of the pro-
band, and data from 30 control samples of the Mexican
population obtained from the International HapMap3
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The SNP 6.0 array contains 1.8 million probes (from
which 906,600 correspond to SNPs), with a median
inter-marker distance of 680 bp. All of the microarray
procedures were performed according to the manufac-
turer’s instructions. Genotype calls were generated with
Genotyping Console 4.1 (Affymetrix Inc.), and copy-
number analyses were performed using SNP & Variation
Suite 7.5.6 (Golden Helix Inc., Bozeman, MT, USA). The
human genome assembly used was GRCh 37/hg19 (Feb
2009).
The microarray findings were validated by quantitative
PCR on samples of the trio and in-house controls. The
Taqman assays were Hs02790577_cn and Hs02374215_cn,
corresponding to the UBA2 and SCN1B deleted genes, re-
spectively. The assays were performed in a StepOne Plus
instrument following the manufacturer’s protocol, and the
RPPH1 assay (catalogue #4403326) was included as the
copy-number reference. Results were analysed using Copy
Caller 2.0 software. All materials, instruments, and soft-
ware used for qPCR analysis were from Life Technologies
(Foster City, CA).Consent
Written informed consent was obtained from the par-
ents of the patient for the publication of this case report.
A copy of the written consent is available for review by
the Editor-in-Chief of this journal.Additional files
Additional file 1: Figure S1. Trio quantitative PCR analyses confirmed
the de novo deletion of the (a) UBA2 and (b) SCN1B genes in the proband.
The patient’s sample showed a delayed amplification curve relative to his
parents and control samples, indicating a single copy of each gene. The
amplification curve of each sample is according to the colour chart at the
left, and target genes are indicated with arrows. The ribonuclease PRNA
component H1 gene (RPPH1) was used as a diploid reference assay, and
two different sets of pooled samples were included for comparison (sets A
and B, 10 healthy controls each). Assays were performed in quadruplicate.
Additional file 2: Trio SNP analysis in chromosome 19q.
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